ERBB2 and cancer: Inhibition of the Transforming Growth Factor-beta-1 (TGF-β1) pathway has been shown to block the EMT process in cancer cells in vitro, and, consequently, to restore the cytotoxic activity of HER2-specific CAR-T cells.